Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 3Phase 1 2

Status

Completed 2Withdrawn 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 5Genitourinary 3Tumor-Agnostic 1Sarcoma 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Prostatic Neoplasms 3

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × ixabepilone × Genitourinary × Clear all
NCT01079793 2020-08-20

Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery

University of Texas Southwestern Medical Center

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT00331344 2017-10-31

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

National Cancer Institute (NCI)

Phase 1/2 Completed
100 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00025194 2013-06-24

Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡